Bapcor stock has recently seen an updated price target, attributed to a modest rise in the discount rate from 7.70% to 8.02%. This shift reflects both optimism about the company’s long-term valuation as well as caution prompted by broader economic dynamics. Stay tuned to discover how you can keep up with the evolving narrative around Bapcor and its outlook.

Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Bapcor.

What Wall Street Has Been Saying

Analyst sentiment on Bapcor has centered around recent changes in price targets and ongoing assessments of the company’s outlook. The following sections highlight the most recent Street research inputs.

🐂 Bullish Takeaways

Thiago Batista at UBS has demonstrated continued confidence in Bapcor, raising the firm’s price target for Credicorp to $318 from $257, while maintaining a Buy rating. This upward revision reflects expectations for favorable longer-term valuation. Analysts highlighting bullish trends commonly reward the company for its execution quality and strong cost control. Transparency and sustained growth momentum remain key drivers in their rationale.

🐻 Bearish Takeaways

While the prevailing analyst update is positive, reservations persist around current valuation and the extent to which upside is already reflected in the share price. Some analysts maintain a cautious approach due to persistent near-term risks. However, no specific downward revisions or negative outlooks have been published in the most recent inputs.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!ASX:BAP Community Fair Values as at Nov 2025

What's in the News

Bapcor has released new earnings guidance for the first half of 2026, projecting Statutory Net Profit after Tax (NPAT) between $3 million and $7 million. This assessment does not include any potential impairments from its New Zealand segment. The company also forecasts its full-year 2026 Statutory NPAT to fall within the $40 million to $50 million range. This continues to exclude the impact of possible first half 2026 impairment charges associated with its New Zealand operations. Market attention remains on Bapcor's New Zealand performance, with analysts noting that any additional impairment charges could influence reported earnings and future guidance. Investors are closely watching how Bapcor manages ongoing economic headwinds and the execution of its operational strategies in the coming quarters.

Story Continues

How This Changes the Fair Value For Bapcor

The discount rate has risen slightly, increasing from 7.70% to 8.02%. Future P/E has edged up marginally, from 15.06x to 15.19x. Fair value remains unchanged at A$3.21. Revenue growth and net profit margin show negligible changes and remain stable at approximately 1.27% and 4.39% respectively.

🔔 Never Miss an Update: Follow The Narrative

A Narrative is a dynamic story investors create to connect a company’s financial forecast and fair value with real-world developments. On Simply Wall St’s Community page, millions of users track Narratives to understand when the fair value and the share price become misaligned. Narratives update automatically with news and earnings and offer an accessible way to decide when to buy or sell.

Read the original Narrative for Bapcor to stay ahead of every key development, including:

Efficiency initiatives and investments in automation that aim to drive margin recovery and future earnings growth. Strategic network optimization and online expansion designed to defend Bapcor’s market share and support long-term profitability. Risks and opportunities from restructuring, competition, and exposure to Australia and New Zealand, as well as how these factors may impact valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include BAP.AX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments